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The International Price Index's Impact on Revenue in the Pharmaceutical Industry
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To date, pharmaceuticalspending in the United States is significantlyhigher than in other

countries, a fact which is especially true of spending under Medicare PartB. To address
the high cost ofpharmaceuticalsunderMedicarePartB, the UnitedStates' Departmentof
Health and Human Services has proposed a policy, the InternationalPrice Index. This
policy would change the regulationson Medicare reimbursementof physicians and other

consumers drugs covered under PartB. Currently, Medicare's reimbursementfor PartB
drugs is not limited to any specific price point, the International Price Index would
establish an upper limit on the amount that Medicare is allowed to pay. This limit would
be based upon the average price that other countriespay, thus bringing the price in the
United States closer to internationalprices.
Critics speculate the InternationalPrice Index will drive the price of drugs covered by
MedicarePartB so low that the pharmaceuticalindustry will lose revenue, which will have
the unintended consequence of slowing down the pace of pharmaceuticaldevelopment as
companies will no longer invest in researchand development at the same rate. This paper
responds to these criticisms in two ways. First, it analyzes the relationshipbetween revenue

and research and development in the pharmaceutical industry. Second, it predicts the
InternationalPriceIndex's effect on the prices ofpharmaceuticalsin the countries that are
referenced within the policy. This prediction is based on an analysis of the economics in
the pharmaceuticalindustry and a comparison to the Robinson Patman Act. The result
shows that investments into research and development will likely be unchanged because

the InternationalPrice Index need only have a moderate degree of success in spreading
out the costs ofpharmaceuticalsin order to avoid any substantialchange in revenue within
the pharmaceuticalindustry.
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No Ordinary Process: The Flaws in Illinois Courts' Use of Remote Video
Technology in Mental Health Trials
Matthew R. Davison ...................................................................................................... 137

This article discusses and criticizes Illinois courts' use of remote video conference
technology in mental-health trials during the COVID-19 pandemic. It contends that, while
the Illinois Supreme Court issued rules and guidance that directedhow local courts should
implement video conference technology with purpose and accommodations, the local
courts (including the largest circuit court in Illinois) instead mandated remote video
technology for mental health trials as a panacea without regard to participants'
preferences, objections, or disabilities. As detailed further, the issues only compound
because of a separate shortcoming where, unlike other remote hearings and trials which
are widely available to view by the public, no such public access links accompany any of
these remote video mental health trials. Meaning, for the majority of 2020 and continuing
to date (as of Feb. 20, 2021), trials involvingfundamental liberty interests (i.e., involuntary

commitments and forced administration of medications or electroconvulsive therapy)
occurred out of public view, in a manner inconsistent with law and policy.

Catching Up with Convergence: Strategies for Bringing Together the Fragmented
Regulatory Governance of Brain-Machine Interfaces in the United States
Walter G. Johnson...........................................................................................................177
After a decade of stalledinnovation, the pastfive years have seen brain-machineinterfaces

("BMs") make rapid advances through the convergence of ideasfrom and progress in
other emerging technologies. However, the sheer complexity of these neurotechnologies
will produce a complicated and incomplete regulatory environment. Regulating these
neurotechnologieswill demand managing risks at the intersection of safety, effectiveness,
cyber-security, consumer protection, equity, data privacy, personal autonomy, and dual

use. These convergent risks compound the thorny "pacingproblem," in which accelerating
technological innovation can overtake public regulators and their efforts to understand

and manage risks. In the United States, the Food and Drug Administration ("FDA") and
Federal Trade Commission ("FTC') already have authority to regulate some
neurotechnologies. However, these agencies' jurisdictions are over different subject
matters which overlap when applied to BMIs due to technological convergence. This
convergence will ultimately create significant regulatory problems for BMIs and
neurotechnologies generally. Managing the complexities of convergence in BMIs will
require a policy response defined by early action, regulatory coordination, and political
supportfrom lawmakers.

Global Health Law & Governance Amidst the Pandemic
Julien Chaisse and Nilanjan Banik ................................................................................ 207
The phrase "desperate times require desperate measures" holds true in the context of the
mitigation efforts initiatedat both the domestic and internationallevels by governments,
corporations,multilateralinstitutions, and individuals to combat the COVID-19 pandemic.
The pandemic has crippled the global economy and has showcased the urgent need for
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better health infrastructure and efficient accessibility to healthcare services. COVID-19
has presented numerous challenges because of dispute resolution including general
internationaland investment claims and trade law violations. Against this backdrop, this
paperproposes the formation of a health index- the Health InfrastructureIndex (HiI) - as
an alternativeto the existing Human Development Index (HDI) and HealthcareAccess and
Quality (HAQ). In order to understandand tackle domestic health vulnerability, the HiI
includes the availability of skilled medical professionals, government expenditure on
healthcare and the likelihood of internationalfunding. Internationalcooperation as a
response is emerging as a key factor to fight against COVID-19. The HI index highlights
critical areas where domestic or multilateralinterventions are required. With the inherent
limitations of conventional health indices, the HI offers both the possibility of evidenceand research-basedinternationalcoordination of health-relatedpolicies and encourages
participatorydevelopment.
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